Capitalization 80TCr 517.77Cr 43TCr P/E ratio 2025 *
23.3x
P/E ratio 2026 * 20.5x
Enterprise value 60TCr 388.99Cr 33TCr EV / Sales 2025 *
2.42x
EV / Sales 2026 * 2.12x
Free-Float
84.57%
Yield 2025 *
0.86%
Yield 2026 * 0.95%
More valuation ratios * Estimated data
Dynamic Chart
Rohto Pharmaceutical Acquires 51% of Austrian-company Mono Chem-pharm Produkte MT
Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for ?30 million. CI
Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen MT
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update DJ
Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang RE
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang DJ
Rohto Pharmaceutical Co.,Ltd. and Mitsui & Co., Ltd. made an offer acquire 14% stake in Eu Yan Sang International Ltd. CI
Rohto Pharmaceutical Co.,Ltd., Mitsui & Co., Ltd. and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million. CI
FiNC Technologies Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd. CI
Rohto Pharmaceutical's Profit Climbs 21% in Fiscal Nine Months, Lifts Fiscal-Year Outlook MT
Alina Vision Pte Ltd. announced that it has received funding from Fred Hollows Foundation, Rohto Pharmaceutical Co.,Ltd., TVM Capital Healthcare Partners CI
Plantex Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd., Dai-ichi Life Holdings, Inc., RealTechJapan LLC. CI
Rohto Pharmaceutical Co.,Ltd.(TSE:4527) added to S&P Japan Mid Cap 100 CI
More news
1 day-0.14%
1 week+3.19%
Current month+3.53%
1 month+8.79%
3 months+17.00%
6 months+16.49%
Current year+22.76%
More quotes
1 week
3 448.00
Extreme 3448
3 547.00
1 month
3 221.00
Extreme 3221
3 547.00
Current year
2 640.50
Extreme 2640.5
3 547.00
1 year
2 640.50
Extreme 2640.5
4 117.00
3 years
1 433.50
Extreme 1433.5
4 117.00
5 years
1 238.50
Extreme 1238.5
4 117.00
10 years
670.50
Extreme 670.5
4 117.00
More quotes
Insider TitleAgeSince
Director of Finance/CFO - -
Director/Board Member 64 01/20/01
Director/Board Member 58 01/20/01
Insider TitleAgeSince
Chairman 68 01/80/01
Director/Board Member 68 01/07/01
Director/Board Member 60 01/86/01
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.14%+3.19%+16.33%+131.13% 511.03Cr
-2.10%-8.68%+86.11%+252.19% 79TCr
-2.16%-6.97%+62.71%+216.13% 60TCr
+2.58%+3.49%-8.17%-9.03% 37TCr
+1.24%+0.38%+14.07%+62.39% 32TCr
+1.77%+4.14%+22.59%+49.09% 31TCr
+0.07%+5.64%-0.40%-21.25% 25TCr
+0.20%+0.94%+13.41%+44.03% 24TCr
+0.08%-2.67%+5.47%+13.82% 22TCr
+0.71%+0.74%+42.92%+35.48% 18TCr
Average -0.40%-0.24%+25.50%+77.40% 32.67TCr
Weighted average by Cap. -0.63%-1.99%+38.53%+114.77%
See all sector performances

Financials

Ratios2025 *2026 *
Net sales 30TCr 196.32Cr 16TCr 33TCr 215.49Cr 18TCr
Net income 3.42TCr 22Cr 1.86TCr 3.88TCr 25Cr 2.11TCr
Net Debt -6.46TCr -42Cr -3.52TCr -9.33TCr -61Cr -5.08TCr
More financial data * Estimated data
Logo Rohto Pharmaceutical Co.,Ltd.
ROHTO PHARMACEUTICAL CO., LTD. is a Japan-based company principally engaged in the health and beauty care area. The Company primarily provides eye care-related products, including eye drops and eye lotions; skin care-related products, including dermatological preparations, lip balms, sunscreens and functional cosmetics; oral medication and food-related products, including digestive medicines, Chinese herbal medicines and supplements, as well as extracorporeal test drugs and other products. The Company operates its business in domestic market and overseas markets, including Europe, Asia and America.
Employees
7,259
Calendar
More about the company
Date Price Change Volume
24/24/24 3,490.00 ¥ -0.14% 462,200
23/24/23 3,495.00 ¥ -0.26% 574,500
22/24/22 3,504.00 ¥ +0.95% 686,600
19/24/19 3,471.00 ¥ -1.03% 511,300
18/24/18 3,507.00 ¥ +1.36% 949,800

Delayed Quote Japan Exchange, July 24, 2024 at 11:30 am IST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3,490.00JPY
Average target price
3,958.89JPY
Spread / Average Target
+13.44%
Consensus